Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002045 · ClinicalTrials.gov registry record · NA
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
A NA study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002045 is a NA study of HIV Infections that has completed, run by Glaxo Wellcome. The trial reports 1 study location across 1 state.
The verdict
NCT00002045, a NA study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.
Conditions Studied
Interventions
- DRUG Zidovudine
Study Locations (1)
North Carolina
- Glaxo Wellcome Inc - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002045
The ClinicalTrials.gov registry entry for NCT00002045 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.
NCT00002045 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00002045 about?
NCT00002045 is a clinical study titled "A Prospective Double-Blind Study of Retrovir in Early HIV Infection". To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discont...
What is the current status of trial NCT00002045?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002045 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002045?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002045?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002045 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.